SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
PSDV - pSivida Limited
An SI Board Since November 2005
Posts SubjectMarks Bans Symbol
421 8 0 PSDV
Emcee:  John McCarthy Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
221SurModics - Genentech - Lucentis Genentech, SurModics Aiming for Microparticle John McCarthy-10/7/2009
220Good news for Albertans in the fight against leading cause of age-related visionJohn McCarthy-10/6/2009
219Reducing Treatments an Important Finding for Patients With Age-Related Macular DJohn McCarthy-10/6/2009
218Single Re-treatment Injection of Ranibizumab, Bevacizumab Not Sufficient to RecJohn McCarthy-10/6/2009
217Bevacizumab Injections Superior to Pegaptanib, Photodynamic Therapy for NeovascuJohn McCarthy-10/6/2009
216Combination Therapy Noninferior to Ranibizumab Monotherapy in Patients With Age-John McCarthy-10/6/2009
215John's SCOREBOARD -- (a) <b>Lucentis does WELL in RVO trials</b>John McCarthy-10/5/2009
214Vital treatment to save eyesight denied A PHOTOGRAPHER from St Veep claims the John McCarthy-10/5/2009
213Diabetes is hot, but few see diabetic blindness INDIA Mumbai: Estimates suggJohn McCarthy-10/5/2009
212Avastin Study Patients Develop Congestive Heart Failure, Enrollment Suspended &John McCarthy-10/5/2009
211Search for optimal anti-VEGF dosing strategy in AMD continues NEW YORK — AlthoJohn McCarthy-10/5/2009
210<b>How Cutting Payments for a Drug Could Cost Medicare More</b> MedJohn McCarthy-10/5/2009
209Breathtaking Insanity -- A Rule on Eye Treatment Is Likely to Cost Millions BJohn McCarthy-10/5/2009
208Two Phase III Studies of Lucentis <b>Show Early and Sustained Improvement John McCarthy-10/4/2009
207Hi Arthur Thank you for posting that .... and I will post entire results on thJohn McCarthy-10/4/2009
206finance.yahoo.com News from a competitor......Arthur Radley-10/4/2009
205Retisert - However, even in the 5 µg group, the IOP results compare favoraJohn McCarthy-9/29/2009
204Arthur Yes - the close was BRUTAL ... (AND - I just don't see any "lJohn McCarthy-9/29/2009
203John, The close today got ugly......volume poured in at the close. I'm glad Arthur Radley-9/29/2009
202Garbage.Rawnoc-9/29/2009
201My take! 1) PSDV agreed to a 24 month time frame. 2) The issue isn't aboutArthur Radley-9/29/2009
200Arthur - If you get a chance ..... a) Assume I was doing a 36 month trial b) AJohn McCarthy-9/29/2009
199Arthur <i>Am I misinterpreting the data? It appears the low dosage is prJohn McCarthy-9/29/2009
198Am I misinterpreting the data? It appears the low dosage is pretty low efficacyArthur Radley-9/29/2009
197The PK Trials - 3 months to 18 months ... ================= <b>3 Month ReJohn McCarthy-9/29/2009
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News